Clinical implications of gene expression profiling of acute myeloid leukemia
- 42 Downloads
Since the first demonstration in 1999 that gene expression profiling could distinguish between different variants of acute leukemia, several studies have analyzed patients with acute myeloid leukemia on the basis of cytogenetics, morphologic subgroups, secondary mutations such as FLT3, prognosis, and therapeutic response. This review examines some of these data and attempts to discuss whether these analyses will have clinical applications in diagnosis, prediction of prognosis and response to therapy, disease classification, or individually targeted therapy. It is probable that all these areas will reach the clinical environment eventually, but in the short to medium term, microarrays will be involved only in diagnosis.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 5.Kottaridis PD, Gale RE, Frew ME, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752–1759.PubMedCrossRefGoogle Scholar
- 15.Debernardi S, Lillington DM, Chaplin T, et al.: Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 2003, 37:149–158.PubMedCrossRefGoogle Scholar
- 22.Bullinger L, Dohner K, Bair E, et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350:1605–1616. This paper, and that by Valk et al. [23•], expanded the use of microarrays in AML by using large patient numbers. This also allowed limited clinical outcome data to be incorporated into the array data.PubMedCrossRefGoogle Scholar
- 23.Valk PJ, Verhaak RG, Beijen MA, et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617–1628. The largest study on adult patients with AML published to date. Sixteen distinct disease-related clusters were identified—only some of them related to cytogenetic abnormalities. Some of the remaining clusters contained established mutations such as FLT3 or CEBPβ, but the fact that some clusters remain without known markers indicates that we still do not know the underlying molecular causes of most types of AML.PubMedCrossRefGoogle Scholar
- 28.Haferlach T, Kohlmann A, Schnittger S, et al.: Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005, 106:1189–1198. A large study of nearly 1000 different leukemia samples covering both acute and chronic leukemia types and subtypes, which showed that gene expression profiles or lists can be identified that could reproduce 12 predefined cytogenetic and morphologic groups with a high specificity (> 97% in 11 of the 12 groups). This evidence could form the basis of a diagnostic gene chip to complement and enhance conventional diagnostic techniques such as immunophenotyping, cytogenetics, FISH, or RT-PCR.PubMedCrossRefGoogle Scholar
- 34.European LeukemiaNET. http://www.leukemia-net.org. Accessed September 13, 2005.Google Scholar
- 35.Haferlach T, Kohlmann A, Basso G, et al.: A multi-center and multi-national program to assess the clinical accuracy of the molecular subclassification of leukemia by gene expression profiling. Blood 2005, In press.Google Scholar